Novotech CRO and Clinical Network Services (CNS) Announced as Finalists in 2019 Clinical & Research Excellence Awards by Informa Pharma Intelligence

You are here

BOSTON – February, 25 – Novotech CRO and subsidiary Clinical Network Services (CNS) have been named finalists in the prestigious Clinical Research & Excellence Awards for Clinical Partnership of the Year, which recognizes outstanding work across the global clinical research enterprise.

The 2019 winners will be announced at a ceremony on Thursday, 2 May at the Hyatt Regency Boston, MA, with distinguished leaders in the biopharmaceutical, CRO, and diagnostic industries from all corners of the globe.

Headquartered in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech’s strong Asia Pacific presence includes running clinical trials in all key regional markets. Novotech also has worldwide reach through the company's network of strategic partners.

The CNS BioDesk offers our international clients expert intelligent global product development and regulatory affairs consultancy specialising in readying products to swiftly enter the clinic or gain marketing approval in the USA.

The CARE Awards 2019 features 11 categories, which showcase significant accomplishments and highlight innovation across the industry – from rare disease drug development and patient centricity in trials and research, to product and technological development, clinical results and collaborative efforts between individuals, departments, or companies. Entries are judged independently by a panel of experts from all core sectors of the clinical R&D industry.

Novotech CEO Dr John Moller said:

Novotech CRO and its subsidiary CNS value this recognition from such a respected industry organisation as Informa Pharma Intelligence.

The Award is for Clinical Partnership of the Year which is further validation of the significance of our 2 organisations coming together to deliver unparalleled clinical services in the Asia-Pacific.

Novotech is now the largest regional CRO with 10 offices across the Asia-Pacific backed by 11 major partnerships with leading medical institutions which offer our clients unprecedented access to KOLs, PIs, research teams and vast patient populations to expertly and rapidly deliver clinical research.

Novotech uses the same data technology used by the leading global CROs while offering deep in-country regulatory, feasibility, startup and monitoring expertise, making it the ideal regional partner for global studies.

You can view the full list of finalists here:

About Informa Pharma Intelligence
Informa Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit


About CNS
About Clinical Network Services 
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA, who create value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner. CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical services and biometrics team. CNS’ regional clinical advantage is driven by the extremely pragmatic regulatory environment in Australia and New Zealand that makes it possible for clients to enter the clinic quickly, without prior regulatory approval. 
CNS offers a uniquely differentiated, customer-orientated, suite of services to clients which enables CNS to guide products efficiently through critical post-discovery development and into initial human trials. Throughout, CNS takes a global development/ regulatory strategic approach to ensure that value is added at every stage of the product development life cycle.
Further information about CNS and its intelligent development services can be found at

About BioDesk:
CNS’ BioDesk is an expert consulting team offering CMC/manufacturing, toxicology, clinical and regulatory affairs consulting services for readying products to enter clinical trials or marketing approval. The BioDesk team consists of experienced chemists, toxicologists, medical writers, regulatory affairs specialists and experienced clinicians based in Australia, Europe and the USA. BioDesk works closely with clients to design and implement manufacturing operations and non-clinical plans, mindful of commercial timelines and budgets. BioDesk further adds value by ensuring that a global regulatory standard is inherent within client development programs. After submission of a marketing approval, BioDesk collaboratively works with the experienced Australian/New Zealand clinical operations and biometrics teams to realise client goals.
Further information about BioDesk services can be found at